Doximity (NYSE:DOCS) Price Target Cut to $27.00 by Analysts at Needham & Company LLC

Doximity (NYSE:DOCS) had its price target cut by Needham & Company LLC from $55.00 to $27.00 in a report released on Thursday, MarketBeat Ratings reports. They currently have a buy rating on the stock.

DOCS has been the topic of several other research reports. KeyCorp cut Doximity from an “overweight” rating to a “sector weight” rating in a research note on Thursday. Bank of America cut their price target on Doximity from $56.00 to $47.00 and set a “buy” rating on the stock in a research note on Thursday, April 16th. Robert W. Baird reiterated a “neutral” rating and issued a $18.00 price target (down from $40.00) on shares of Doximity in a research note on Thursday. Piper Sandler boosted their price objective on Doximity from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Finally, Freedom Capital upgraded Doximity to a “strong-buy” rating in a research note on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and thirteen have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $30.62.

Doximity Stock Performance

NYSE:DOCS opened at $17.94 on Thursday. Doximity has a one year low of $17.15 and a one year high of $76.51. The stock has a 50-day simple moving average of $24.09. The firm has a market capitalization of $3.31 billion, a PE ratio of 18.12, a price-to-earnings-growth ratio of 1.66 and a beta of 1.36.

Doximity declared that its board has approved a stock buyback plan on Thursday, February 5th that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to purchase up to 8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Insider Activity at Doximity

In other news, insider Siddharth Sitaram sold 2,427 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $21.09, for a total transaction of $51,185.43. Following the completion of the transaction, the insider directly owned 86,705 shares of the company’s stock, valued at approximately $1,828,608.45. This represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $26.06, for a total value of $234,540.00. Following the transaction, the director directly owned 19,839 shares of the company’s stock, valued at $517,004.34. This trade represents a 31.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,055 shares of company stock valued at $456,061 over the last ninety days. Corporate insiders own 31.30% of the company’s stock.

Hedge Funds Weigh In On Doximity

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DOCS. Carmignac Gestion grew its holdings in Doximity by 355.9% in the 4th quarter. Carmignac Gestion now owns 1,893,026 shares of the company’s stock worth $83,831,000 after buying an additional 1,477,798 shares in the last quarter. SG Americas Securities LLC grew its holdings in Doximity by 3,403.2% in the 1st quarter. SG Americas Securities LLC now owns 1,408,597 shares of the company’s stock worth $32,820,000 after buying an additional 1,368,388 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in Doximity by 325,436.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,298,891 shares of the company’s stock worth $57,515,000 after buying an additional 1,298,492 shares in the last quarter. Federated Hermes Inc. grew its holdings in Doximity by 3,422.7% in the 4th quarter. Federated Hermes Inc. now owns 1,249,085 shares of the company’s stock worth $55,309,000 after buying an additional 1,213,627 shares in the last quarter. Finally, Capital World Investors grew its holdings in Doximity by 25.7% in the 3rd quarter. Capital World Investors now owns 5,381,431 shares of the company’s stock worth $393,652,000 after buying an additional 1,101,848 shares in the last quarter. 87.19% of the stock is owned by institutional investors.

Trending Headlines about Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted EPS of $0.26, ahead of one analyst estimate, and revenue rose 5.1% year over year to $145.37 million, showing the core business is still growing. Doximity Earnings Report
• Positive Sentiment: Commentary around AI adoption and customer growth suggests Doximity’s platform remains engaged with clinicians, which could support longer-term monetization. Zacks Coverage
• Neutral Sentiment: The company maintained strong profitability metrics, including a 23.84% return on equity and 37.54% net margin, but those figures were overshadowed by weaker near-term outlook commentary. Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Doximity missed the broader analyst consensus on EPS, which disappointed traders looking for a stronger earnings beat. Doximity Lags Q4 Earnings Estimates
• Negative Sentiment: Most importantly, fiscal 2027 revenue guidance came in below Wall Street expectations, reinforcing concerns that growth is slowing while AI-related investment is pressuring margins. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: Multiple analysts cut price targets after the report, including JPMorgan, Truist, BMO Capital, Mizuho, and Needham, adding to the negative sentiment around the stock. Analyst Target Cuts
• Negative Sentiment: Unusual put-option buying and an insider share sale added to the cautious tone, even though the insider transaction was part of a pre-arranged trading plan. Insider Trade Disclosure

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.